JP3997491B2 - カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 - Google Patents
カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 Download PDFInfo
- Publication number
- JP3997491B2 JP3997491B2 JP2006542433A JP2006542433A JP3997491B2 JP 3997491 B2 JP3997491 B2 JP 3997491B2 JP 2006542433 A JP2006542433 A JP 2006542433A JP 2006542433 A JP2006542433 A JP 2006542433A JP 3997491 B2 JP3997491 B2 JP 3997491B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituent
- methoxy
- methyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1OC(c2ccccc2)=N*1COc(ccc(*)c1)c1OC Chemical compound CC1OC(c2ccccc2)=N*1COc(ccc(*)c1)c1OC 0.000 description 8
- YLGKEUXUEBUKEI-UHFFFAOYSA-N CCCCCC(C(O)=O)Oc1cccc2c1c(cccc1)c1[nH]2 Chemical compound CCCCCC(C(O)=O)Oc1cccc2c1c(cccc1)c1[nH]2 YLGKEUXUEBUKEI-UHFFFAOYSA-N 0.000 description 2
- XKVMNJNFDRQAAM-UHFFFAOYSA-N Cc1c(COc(ccc(CCl)c2)c2OC)nc(-c2ccccc2)[o]1 Chemical compound Cc1c(COc(ccc(CCl)c2)c2OC)nc(-c2ccccc2)[o]1 XKVMNJNFDRQAAM-UHFFFAOYSA-N 0.000 description 2
- IUWAZTWHBAHWAU-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1cccc2c1c(cccc1)c1[nH]2 Chemical compound CC(C)(C(O)=O)Oc1cccc2c1c(cccc1)c1[nH]2 IUWAZTWHBAHWAU-UHFFFAOYSA-N 0.000 description 1
- XYWJYJBVSCHKGT-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1cccc2c1c(cccc1)c1[n]2Cc(cc1)cc(OC)c1OCc1c(C)[s]c(-c2ccccc2)n1 Chemical compound CC(C)(C(O)=O)Oc1cccc2c1c(cccc1)c1[n]2Cc(cc1)cc(OC)c1OCc1c(C)[s]c(-c2ccccc2)n1 XYWJYJBVSCHKGT-UHFFFAOYSA-N 0.000 description 1
- KZQRVTWGCQGRNH-UHFFFAOYSA-N CC(CCOC(C12)=CC=CC1N(Cc(cc1)cc(OC)c1OCC1=C(C)OC(c3ccccc3)N1)c1c2cccc1)C(N=O)=O Chemical compound CC(CCOC(C12)=CC=CC1N(Cc(cc1)cc(OC)c1OCC1=C(C)OC(c3ccccc3)N1)c1c2cccc1)C(N=O)=O KZQRVTWGCQGRNH-UHFFFAOYSA-N 0.000 description 1
- SBQSXCVJXDDTTK-UHFFFAOYSA-N CC(CCOc1cccc2c1c(cccc1)c1[nH]2)C(O)=O Chemical compound CC(CCOc1cccc2c1c(cccc1)c1[nH]2)C(O)=O SBQSXCVJXDDTTK-UHFFFAOYSA-N 0.000 description 1
- SGXCUZOLAKGDDF-UHFFFAOYSA-N CC(CCOc1cccc2c1c(cccc1)c1[n]2Cc(cc1)cc(OC)c1OCc1c(C)[o]c(-c2ccccc2)n1)C(N=O)=O Chemical compound CC(CCOc1cccc2c1c(cccc1)c1[n]2Cc(cc1)cc(OC)c1OCc1c(C)[o]c(-c2ccccc2)n1)C(N=O)=O SGXCUZOLAKGDDF-UHFFFAOYSA-N 0.000 description 1
- ZQOQEJCWRCXHCG-UHFFFAOYSA-N CCCCC(C(O)=O)Oc1cccc2c1c(cccc1)c1[nH]2 Chemical compound CCCCC(C(O)=O)Oc1cccc2c1c(cccc1)c1[nH]2 ZQOQEJCWRCXHCG-UHFFFAOYSA-N 0.000 description 1
- WNAHFRVFUZRMJX-UHFFFAOYSA-N Cc1c(COC)nc(-c2ccccc2)[o]1 Chemical compound Cc1c(COC)nc(-c2ccccc2)[o]1 WNAHFRVFUZRMJX-UHFFFAOYSA-N 0.000 description 1
- VKWZJPLDNLENEJ-UHFFFAOYSA-N Cc1c(COc(ccc(C[n](c2c3cccc2)c2c3c(OCC(O)=O)ccc2)c2)c2OC)nc(-c2ccc[o]2)[o]1 Chemical compound Cc1c(COc(ccc(C[n](c2c3cccc2)c2c3c(OCC(O)=O)ccc2)c2)c2OC)nc(-c2ccc[o]2)[o]1 VKWZJPLDNLENEJ-UHFFFAOYSA-N 0.000 description 1
- FZVCJCFVCDCBDZ-UHFFFAOYSA-N Cc1c(COc(ccc(C[n](c2c3cccc2)c2c3c(OCCCC(O)=O)ccc2)c2)c2OC)nc(-c2ccccc2)[o]1 Chemical compound Cc1c(COc(ccc(C[n](c2c3cccc2)c2c3c(OCCCC(O)=O)ccc2)c2)c2OC)nc(-c2ccccc2)[o]1 FZVCJCFVCDCBDZ-UHFFFAOYSA-N 0.000 description 1
- SWXQTXQSLAAZQD-UHFFFAOYSA-N Cc1c(COc2ccc(C[n](c3c4cccc3)c3c4c(OC(C(O)=O)c4ccccc4)ccc3)cc2OC)nc(-c2ccc[o]2)[o]1 Chemical compound Cc1c(COc2ccc(C[n](c3c4cccc3)c3c4c(OC(C(O)=O)c4ccccc4)ccc3)cc2OC)nc(-c2ccc[o]2)[o]1 SWXQTXQSLAAZQD-UHFFFAOYSA-N 0.000 description 1
- PIDOLNRPEHSPNI-ONGXEEELSA-N O=C1OC[C@@](C2)([C@@H]2c2ccccc2)N1 Chemical compound O=C1OC[C@@](C2)([C@@H]2c2ccccc2)N1 PIDOLNRPEHSPNI-ONGXEEELSA-N 0.000 description 1
- RMCWOSMNBMMDPL-UHFFFAOYSA-N O=CC1CC=CC1 Chemical compound O=CC1CC=CC1 RMCWOSMNBMMDPL-UHFFFAOYSA-N 0.000 description 1
- UEOHATPGKDSULR-UHFFFAOYSA-N Oc1cccc2c1c1ccccc1[nH]2 Chemical compound Oc1cccc2c1c1ccccc1[nH]2 UEOHATPGKDSULR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004316872 | 2004-10-29 | ||
| JP2004316872 | 2004-10-29 | ||
| PCT/JP2005/020250 WO2006046779A1 (ja) | 2004-10-29 | 2005-10-28 | カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP3997491B2 true JP3997491B2 (ja) | 2007-10-24 |
| JPWO2006046779A1 JPWO2006046779A1 (ja) | 2008-05-22 |
Family
ID=36227999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542433A Expired - Fee Related JP3997491B2 (ja) | 2004-10-29 | 2005-10-28 | カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8329913B2 (enExample) |
| EP (1) | EP1852433B1 (enExample) |
| JP (1) | JP3997491B2 (enExample) |
| KR (1) | KR101223820B1 (enExample) |
| CN (1) | CN101048402B (enExample) |
| AT (1) | ATE534646T1 (enExample) |
| AU (1) | AU2005297800B2 (enExample) |
| CA (1) | CA2585642C (enExample) |
| CY (1) | CY1112649T1 (enExample) |
| DK (1) | DK1852433T3 (enExample) |
| ES (1) | ES2378177T3 (enExample) |
| PL (1) | PL1852433T3 (enExample) |
| PT (1) | PT1852433E (enExample) |
| SI (1) | SI1852433T1 (enExample) |
| TW (1) | TW200635922A (enExample) |
| WO (1) | WO2006046779A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393181B2 (en) | 2004-09-17 | 2008-07-01 | The Penn State Research Foundation | Expandable impeller pump |
| AU2007230945B2 (en) | 2006-03-23 | 2013-05-02 | The Penn State Research Foundation | Heart assist device with expandable impeller pump |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP2185544B1 (en) | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
| US8535211B2 (en) | 2009-07-01 | 2013-09-17 | Thoratec Corporation | Blood pump with expandable cannula |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| CN102382037B (zh) * | 2010-09-03 | 2016-01-20 | 中国医学科学院药物研究所 | 苯丙酸类化合物及其制法和药物用途 |
| US8597170B2 (en) | 2011-01-05 | 2013-12-03 | Thoratec Corporation | Catheter pump |
| US8485961B2 (en) | 2011-01-05 | 2013-07-16 | Thoratec Corporation | Impeller housing for percutaneous heart pump |
| WO2012094641A2 (en) | 2011-01-06 | 2012-07-12 | Thoratec Corporation | Percutaneous heart pump |
| WO2012094535A2 (en) | 2011-01-06 | 2012-07-12 | Thoratec Corporation | Percutaneous heart pump |
| US9872947B2 (en) | 2012-05-14 | 2018-01-23 | Tc1 Llc | Sheath system for catheter pump |
| US8721517B2 (en) | 2012-05-14 | 2014-05-13 | Thoratec Corporation | Impeller for catheter pump |
| US9327067B2 (en) | 2012-05-14 | 2016-05-03 | Thoratec Corporation | Impeller for catheter pump |
| US9446179B2 (en) | 2012-05-14 | 2016-09-20 | Thoratec Corporation | Distal bearing support |
| DE102013008159A1 (de) | 2012-05-14 | 2013-11-14 | Thoratec Corporation | Mantelsystem für Katheterpumpe |
| GB2504176A (en) | 2012-05-14 | 2014-01-22 | Thoratec Corp | Collapsible impeller for catheter pump |
| EP4186557A1 (en) | 2012-07-03 | 2023-05-31 | Tc1 Llc | Motor assembly for catheter pump |
| US9358329B2 (en) | 2012-07-03 | 2016-06-07 | Thoratec Corporation | Catheter pump |
| US9421311B2 (en) | 2012-07-03 | 2016-08-23 | Thoratec Corporation | Motor assembly for catheter pump |
| US11077294B2 (en) | 2013-03-13 | 2021-08-03 | Tc1 Llc | Sheath assembly for catheter pump |
| JP6530367B2 (ja) | 2013-03-13 | 2019-06-12 | ティーシーワン エルエルシー | 流体導出入システム |
| US11033728B2 (en) | 2013-03-13 | 2021-06-15 | Tc1 Llc | Fluid handling system |
| EP4190376A1 (en) | 2013-03-15 | 2023-06-07 | Tc1 Llc | Catheter pump assembly including a stator |
| US9308302B2 (en) | 2013-03-15 | 2016-04-12 | Thoratec Corporation | Catheter pump assembly including a stator |
| US10583232B2 (en) | 2014-04-15 | 2020-03-10 | Tc1 Llc | Catheter pump with off-set motor position |
| WO2015160990A1 (en) | 2014-04-15 | 2015-10-22 | Thoratec Corporation | Catheter pump introducer systems and methods |
| EP3479854A1 (en) | 2014-04-15 | 2019-05-08 | Tc1 Llc | Catheter pump with access ports |
| WO2015160943A1 (en) | 2014-04-15 | 2015-10-22 | Thoratec Corporation | Sensors for catheter pumps |
| WO2016028644A1 (en) | 2014-08-18 | 2016-02-25 | Thoratec Corporation | Guide features for percutaneous catheter pump |
| US9675738B2 (en) | 2015-01-22 | 2017-06-13 | Tc1 Llc | Attachment mechanisms for motor of catheter pump |
| WO2016118781A2 (en) | 2015-01-22 | 2016-07-28 | Thoratec Corporation | Motor assembly with heat exchanger for catheter pump |
| EP3247420B1 (en) | 2015-01-22 | 2019-10-02 | Tc1 Llc | Reduced rotational mass motor assembly for catheter pump |
| US9907890B2 (en) | 2015-04-16 | 2018-03-06 | Tc1 Llc | Catheter pump with positioning brace |
| EP3804804A1 (en) | 2016-07-21 | 2021-04-14 | Tc1 Llc | Fluid seals for catheter pump motor assembly |
| EP3808402A1 (en) | 2016-07-21 | 2021-04-21 | Tc1 Llc | Gas-filled chamber for catheter pump motor assembly |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| JP7479278B2 (ja) | 2017-10-06 | 2024-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｃｃ阻害剤を含む併用療法 |
| CN116327749A (zh) * | 2023-04-21 | 2023-06-27 | 重庆医科大学 | Gw9662制备治疗非酒精性脂肪性肝炎药物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT76923A (hu) | 1994-07-27 | 1998-01-28 | Sankyo Company Limited | Muszkarinreceptorokra alloszterikus hatást kifejtő heterociklusos vegyületek |
| JP2001503055A (ja) | 1996-10-30 | 2001-03-06 | イーライ・リリー・アンド・カンパニー | 置換三環化合物群 |
| MY125942A (en) * | 1999-09-07 | 2006-09-29 | Upjohn Co | Aminoalkoxy carbazoles for the treatment of cns diseases |
| AU7559600A (en) | 1999-10-15 | 2001-04-23 | Shionogi & Co., Ltd. | V type and/or x type spla2 inhibitors |
| AU2001267825A1 (en) | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for cirrhosis |
| EP1300159B1 (en) | 2000-06-29 | 2007-10-10 | Anthera Pharmaceuticals, Inc. | Remedies for cancer |
| AU2001267826A1 (en) | 2000-06-29 | 2002-01-08 | Shionogi And Co., Ltd. | Remedies for alzheimer's disease |
| TWI314457B (enExample) | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| ATE353876T1 (de) | 2001-03-28 | 2007-03-15 | Lilly Co Eli | Substituierte carbazole als inhibitoren von spla2 |
| WO2004024939A2 (en) | 2002-09-13 | 2004-03-25 | Georgetown University | Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof |
| US7268157B2 (en) | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
-
2005
- 2005-10-28 PT PT05799893T patent/PT1852433E/pt unknown
- 2005-10-28 AT AT05799893T patent/ATE534646T1/de active
- 2005-10-28 PL PL05799893T patent/PL1852433T3/pl unknown
- 2005-10-28 US US11/666,631 patent/US8329913B2/en not_active Expired - Fee Related
- 2005-10-28 CA CA2585642A patent/CA2585642C/en not_active Expired - Fee Related
- 2005-10-28 CN CN2005800370489A patent/CN101048402B/zh not_active Expired - Fee Related
- 2005-10-28 SI SI200531453T patent/SI1852433T1/sl unknown
- 2005-10-28 WO PCT/JP2005/020250 patent/WO2006046779A1/ja not_active Ceased
- 2005-10-28 DK DK05799893.2T patent/DK1852433T3/da active
- 2005-10-28 KR KR1020077009734A patent/KR101223820B1/ko not_active Expired - Fee Related
- 2005-10-28 ES ES05799893T patent/ES2378177T3/es not_active Expired - Lifetime
- 2005-10-28 EP EP05799893A patent/EP1852433B1/en not_active Expired - Lifetime
- 2005-10-28 TW TW094137797A patent/TW200635922A/zh not_active IP Right Cessation
- 2005-10-28 JP JP2006542433A patent/JP3997491B2/ja not_active Expired - Fee Related
- 2005-10-28 AU AU2005297800A patent/AU2005297800B2/en not_active Ceased
-
2012
- 2012-01-25 CY CY20121100086T patent/CY1112649T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2006046779A1 (ja) | 2008-05-22 |
| AU2005297800A1 (en) | 2006-05-04 |
| TW200635922A (en) | 2006-10-16 |
| EP1852433A4 (en) | 2010-07-21 |
| CA2585642C (en) | 2013-04-02 |
| CY1112649T1 (el) | 2016-02-10 |
| EP1852433A1 (en) | 2007-11-07 |
| KR20070072554A (ko) | 2007-07-04 |
| AU2005297800B2 (en) | 2011-02-03 |
| US8329913B2 (en) | 2012-12-11 |
| CN101048402B (zh) | 2011-11-09 |
| ATE534646T1 (de) | 2011-12-15 |
| DK1852433T3 (da) | 2012-01-30 |
| CA2585642A1 (en) | 2006-05-04 |
| PT1852433E (pt) | 2012-02-08 |
| WO2006046779A1 (ja) | 2006-05-04 |
| TWI359148B (enExample) | 2012-03-01 |
| US20100286210A1 (en) | 2010-11-11 |
| CN101048402A (zh) | 2007-10-03 |
| KR101223820B1 (ko) | 2013-01-17 |
| SI1852433T1 (sl) | 2012-06-29 |
| PL1852433T3 (pl) | 2012-05-31 |
| ES2378177T3 (es) | 2012-04-09 |
| EP1852433B1 (en) | 2011-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3997491B2 (ja) | カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩 | |
| JP5290749B2 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JP4790969B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
| JP4276074B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
| US7528160B2 (en) | Fused heterocyclic derivatives as PPAR modulators | |
| KR101710340B1 (ko) | 퍼옥시좀 증식제 활성화 수용체의 활성화제 | |
| WO2002053547A1 (en) | Alkanoic acid derivatives, process for their production and use thereof | |
| HUP0203431A2 (hu) | Új heterociklusos vegyületek és sóik, és ezeket tartalmazó gyógyszerkészítmények, valamint felhasználásuk | |
| JPWO2002046176A1 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
| WO2008016175A1 (en) | Activator for peroxisome proliferator activated receptor | |
| JPWO2002046154A1 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
| RU2296759C2 (ru) | N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты) | |
| WO2015002150A1 (ja) | 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤 | |
| CA2448639A1 (en) | Novel heterocyclic derivatives and medicinal use thereof | |
| Pingali et al. | Design and synthesis of novel oxazole containing 1, 3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists | |
| WO2006117743A1 (en) | Substituted aromatic compounds as antidiabetic agents | |
| JP3466273B2 (ja) | テトラゾール誘導体、その製造法およびそれを含んでなる医薬 | |
| JP2002322163A (ja) | ピペラジン誘導体 | |
| JPWO2007004733A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
| JPH08311065A (ja) | ベンゾフラン誘導体およびそれを含んでなる医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070712 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070725 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 3997491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100817 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110817 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110817 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120817 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120817 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130817 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |